Lurbinectedin Approval and Tumor Response Rates
Lurbinectedin (branded as Zepzelca) gained accelerated FDA approval in 2020 for metastatic small cell lung cancer (SCLC) patients with disease progression after platinum-based chemotherapy. In the pivotal phase 2 basket trial (PM14-128), the overall response rate (ORR)—patients with confirmed tumor shrinkage—was 35% among 105 SCLC patients. Complete responses occurred in 2%, partial responses in 33%. Median response duration was 5.3 months.[1][2]
Response Rates by Tumor Type
- Small cell lung cancer (SCLC): Highest efficacy in the approval setting, with ORR of 35% (95% CI: 26-45%) and median progression-free survival (PFS) of 3.5 months. Responses were durable in some relapsed cases.[1]
- Other solid tumors (phase 2 exploratory data): Lower rates, e.g., 22% ORR in mesothelioma, 21% in ovarian cancer, 12% in breast cancer, and 6% in head/neck cancers. Responses were rarer in heavily pretreated patients.[2][3]
Durability and Survival Impact
Tumor reductions translated to median overall survival of 9.3 months in SCLC responders versus 5.3 months historically. Progression-free survival reached 5.1 months in combination with doxorubicin for relapsed SCLC, per phase 3 trials.[1][4] Responses often occurred quickly, within 6 weeks of starting treatment.
Factors Affecting Tumor Reduction
Efficacy drops in tumors with high platinum resistance or prior immunotherapy exposure. Patient selection matters: best results in sensitive relapsed SCLC (ORR up to 52% in early relapsers). No strong biomarkers predict response, though ongoing trials test combos with PD-1 inhibitors.[2][5]
How Lurbinectedin Shrinks Tumors
It traps DNA in cells via topoisomerase inhibition, halting replication in rapidly dividing cancer cells. This leads to measurable reductions on CT scans per RECIST criteria (at least 30% shrinkage for partial response).[3]
Comparisons to Standard Treatments
Versus topotecan (prior SCLC standard), lurbinectedin showed higher ORR (35% vs 15%) and better tolerability in head-to-head data, though not superior in overall survival.[4] In combos, it outperforms single-agent chemo in PFS for some subgroups.
Sources
[1]: FDA Approval Summary for Zepzelca
[2]: Trigo et al., Lancet Oncology 2020 (PM14-128 trial)
[3]: Farago et al., JCO 2020
[4]: Phase 3 ORCA trial, ESMO 2023
[5]: ClinicalTrials.gov NCT02454972